Rubin Lab

NEWS

Dr. David Rubin receives the Bruce and Cynthia Sherman Charitable Foundation’s 2020 Sherman Prize

Dr. Rubin was recently announced as one of three recipients of the 2020 Sherman Prize. Sherman Prize recipients “are outstanding individuals who consider the whole patient experience — not just the serious symptoms, but also the psychological and practical components of IBD. Their work is innovative and impactful, and goes well beyond the norm, generating positive benefits on behalf of patients, their families and caregivers, and the future trajectory of the field. They are out-of-the-box thinkers who energize others to enter the fight to overcome Crohn’s and colitis.”

Click Here to View the Full Article

A Cure for Crohn’s: How Close Is It?

Dr. David Rubin discusses advancements in Crohn’s disease treatment.

“And while there isn’t a cure for Crohn’s yet, we’ve come a long way in how we assess and treat it. Treatment used to involve trying a new medicine or therapy and waiting to see if it made you feel better. Now experts know that isn’t the best approach. Yes, we want people with Crohn’s to feel good, but that improvement doesn’t mean the disease is turned off. It’s crucial to get inflammation under control, too, and to get the disease under control. Otherwise, Crohn’s disease can cause permanent damage.”

Read more here.

UPDATE ON IBD AND COVID FOR PATIENTS

Listen to Dr. David Rubin, Professor of Medicine at the University of Chicago Medicine and Chief of the Section of Gastroenterology, Hepatology, and Nutrition, as he provides an update on SARS-CoV2, COVID-19, and what we know and how we can get through this together. His presentation includes the science behind the virus and its spread, information about how the virus affects patients with Crohn’s disease and ulcerative colitis, and an update on the plans for vaccination. He also answers many common questions about testing and going to school or work during the pandemic. (Recorded on Sept 9, 2020, some of the numbers are out of date, but the recommendations at the time of this posting are unchanged.)

Dr. Rubin summarizes IBD treatment options on Medscape ReCAP

 

Dr. Rubin featured on CME Outfitters “COVID-19 + IBD” Episode

The data on COVID-19 is changing rapidly and can be overwhelming. Having been on the frontlines of the pandemic, Dr. David T. Rubin, Dr. Sushila Dalal, and Dr. Miguel Regueiro break down the latest information and best practices for managing patients with IBD and COVID-19 infection or potential infection.

This podcast is available in both video and audio-only formats. This activity offers credit for physicians, nurse practitioners, and physician assistants.

Access the CMEOCast Podcast Episode

HealthCentral features Dr. Rubin on COVID-19 and IBD

In light of the COVID-19 pandemic, Dr. Rubin has been active in informing IBD patients what we know, don’t know, and what experts suggest. This HealthCentral article covers “What People With IBD Need to Know about COVID-19”. Dr. Rubin says the general recommendation is to continue taking your medicine and to be very careful about social distancing. Read more here.

Endoscopic Phenotype: A Potential Predictor of Cuffitis Risk

Advanced IBD Fellow Shintaro Akiyama, MD, PhD presented a Quick Shot of his abstract on pouchitis involving the rectal cuff at Crohn’s and Colitis Congress. MedPage Today reported the results in the article here and Healio reported the results here. Very proud of Dr. Akiyama and his continuing work with characterizing pouchitis.

Hospital-stay duration after IBD surgery not linked to sleep, activity

Second-year Pritzker medical student, Yangtian Yi, received Best Abstract in Surgery at AIBD 2019 for his abstract associating length of stay for IBD surgical patients with data collected from wearable devices. His oral presentation and abstract was reported on by MedPage Today. Check out the article here. More to come from our amazing biosensor study!

Long-Duration Vancomycin Linked to Lower Rates of C. diff Recurrence in IBD

Pritzker medical student Donald Lei’s manuscript was accepted to the American Journal of Gastroenterology. Reuters Health Information reported on the study with comments by Dr. Rubin. “Our study did in fact demonstrate significantly reduced rates of recurrence (testing positive within 8 weeks after antibiotic cessation) and although reinfection rates (testing positive more than 8 weeks after antibiotics) were also lower, this finding was not statistically significant,” he said. “The latter was mainly a statistical power issue.” Congratulations Donald!